First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $37.99M, compared with $0 a year earlier.
Context
- Short-term investments amounted to 13.1% of total assets at the end of Q1 FY2026.
- Short-term investments increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 73.44M USD
- Year-over-year change
- -72.0%
- 2-year CAGR
- -54.5%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.44M | -72.0% |
| FY2024 | 2024-12-31 | 262.29M | -26.1% |
| FY2023 | 2023-12-31 | 354.94M | — |
Short-term Investments vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 short-term investments of $37.99M is the 7th highest of the 10 companies compared; the peer median is $76.76M.
- Short-term investments amounts to 13.1% of total assets for TRAX, versus a peer median of 38.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $104.94M | -9.8% | — | 71.5% | |
CLYMClimb Bio, Inc. | Mar 2026 | $101.21M | +46.6% | -6.5% | 66.4% |
| Jun 2026 | $94.37M | +4568.4% | — | 39.6% | |
| Jun 2026 | $82.3M | — | — | 64.1% | |
| Mar 2026 | $76.76M | +2.4% | -25.7% | 38.6% | |
| Mar 2026 | $59.43M | -71.5% | +22.2% | 14.8% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $37.99M | — | — | 13.1% |
| Mar 2026 | $37.99M | -84.3% | -41.7% | 11.5% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $76.76M | -3.7% | -16.1% | 38.6% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.